Key result
In patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy, 100% maintained or achieved motor milestones and 48.5% experienced an adverse event.
Why the study?
Long-term, real-world effectiveness and safety data of disease-modifying treatments for spinal muscular atrophy are needed for a larger number and broader range of patients than included in clinical trials.
Does onasemnogene abeparvovec monotherapy improve motor milestones and maintain safety in patients with spinal muscular atrophy in a real-world setting?
Observational (n=168)
Yes
Does onasemnogene abeparvovec monotherapy improve motor milestones and maintain safety in patients with spinal muscular atrophy in a real-world setting?
Real-world data from the RESTORE registry confirms the effectiveness and safety of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy, with better outcomes observed in those identified by newborn screening.
Answers are grounded in this paper and cite their sources.
Real-world SMA outcomes with onasemnogene abeparvovec align with trials; extends evidence to broader populations but remains hypothesis-generating pending RCTs.
Background: Long-term, real-world effectiveness and safety data of disease-modifying treatments for spinal muscular atrophy (SMA) are important for assessing outcomes and providing information for a larger number and broader range of SMA patients than included in clinical trials. Objective: We sought to describe patients with SMA treated with onasemnogene abeparvovec monotherapy in the real-world setting. Methods: RESTORE is a prospective, multicenter, multinational, observational registry that captures data from a variety of sources. Results: Recruitment started in September 2018. As of May 23, 2022, data were available for 168 patients treated with onasemnogene abeparvovec monotherapy. Median (IQR) age at initial SMA diagnosis was 1 (0-6) month and at onasemnogene abeparvovec infusion was 3 (1-10) months. Eighty patients (47.6%) had two and 70 (41.7%) had three copies of SMN2, and 98 (58.3%) were identified by newborn screening. Infants identified by newborn screening had a lower age at final assessment (mean age 11.5 months) and greater mean final (SD) CHOP INTEND score (57.0 [10.0] points) compared with clinically diagnosed patients (23.1 months; 52.1 [8.0] points). All patients maintained/achieved motor milestones. 48.5% (n = 81/167) experienced at least one treatment-emergent adverse event (AE), and 31/167 patients (18.6%) experienced at least one serious AE, of which 8/31 were considered treatment-related. Conclusion: These real-world outcomes support findings from the interventional trial program and demonstrate effectiveness of onasemnogene abeparvovec over a large patient population, which was consistent with initial clinical data and published 5-year follow-up data. Observed AEs were consistent with the established safety profile of onasemnogene abeparvovec.
No takes yet. Share an insight, caveat, or question.
Servais et al. (2024) conducted an observational in Spinal muscular atrophy (SMA) (n=168). Onasemnogene abeparvovec monotherapy was evaluated on Maintenance or achievement of motor milestones. In patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy, 100% maintained or achieved motor milestones and 48.5% experienced an adverse event.
Synapse has enriched 10 related papers. Consider them for comparative context: